The approval of this new class of weight loss medications advances the case towards treating obesity as a disease, but these medications are meant to be used alongside lifestyle changes such as nutrition and exercise
Are there side effects specific to non-diabetic GLP-1 users
ALS is classically characterized by painless progressive weakness, causing impaired function of limbs, speech, swallowing, and respiratory function
[33, 34, 35, 36] Mechanism: Typically pre-renal, occurring in the setting of volume depletion from GI losses (nausea, vomiting, diarrhea, reduced oral intake) More frequently seen at higher, obesity-level doses Although generally reno-protective long term, post-marketing data describe acute rises in creatinine following days to weeks of significant GI symptoms Risk factors: Underlying chronic kidney disease Concomitant use of ACE inhibitors, ARBs, diuretics, or SGLT2 inhibitors ED Management: IV fluids Hold GLP-1 and contributing medications Usually reversible with supportive care Future Directions GLP-1 receptor agonists are rapidly evolving beyond their original indications in diabetes and obesity
However, what it did teach me was the importance of varying the type of repetitions you do
In a literature review by Araj-Khodaei et al., it was stated that Berberine induces GLP-1 insulin secretion by altering the gut biome, and promoting the secretion of short chain fatty acids in the large intestine [6]